Principles of early stopping of randomized trials for efficacy: A critique of equipoise and an alternative nonexploitation ethical framework

Kennedy Institute of Ethics Journal

Volumn 15, Issue 2, 2005, Pages 161-178

  Buchanan, David ^a   Miller, Franklin G ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 23744450943     PISSN: 10546863     EISSN: None     Source Type: Journal    
DOI: 10.1353/ken.2005.0010     Document Type: Review

References (35)

1. Appelbaum, Paul S.; Roth, Loren; Lidz, Charles W.; et al. 1987. False Hopes and Best Data: Consent to Research and the Therapeutic Misconception. Hastings Center Report 17 (2): 20-24.
2. Baum, Michael; Buzdar, Aman; Cuzick, Jack; et al. 2002. Anastrozole Alone or in Combination with Tamoxifen Versus Tamoxifen Alone for Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: First Results of the ATAC Randomized Trial. Lancet 359: 2131-39.
3. Braithwaite, Richard B. 1959. Scientific Explanation: A Study of the Function of Theory, Probability and Law in Science. Cambridge, England: Cambridge University Press.
4. Braitman, Leonard E. 1991. Confidence Intervals Assess Both Clinical Significance and Statistical Significance. Annals of Internal Medicine 114: 515-17.
5. Brody, Baruch. 1998. The Ethics of Biomedical Research: An International Perspective. New York: Oxford University Press.
6. Bryant, John, and Wolmark, Norman. 2003. Letrozole after Tamoxifen for Breast Cancer - What Is the Price of Success? NEJM 349: 1855-57.
7. Buchanan, David; Dunn, Barbara; Slutsman, Julia; and Miller, Franklin. 2004. Early Stopping for Efficacy: An Ethical Quandary and a New Approach. Paper presented at the annual meeting of the American Society for Bioethics and the Humanities, 21 October 2004, Philadelphia, PA.
8. Cannistra, Stephen. 2004. The Ethics of Early Stopping Rules: Who Is Protecting Whom? Journal of Clinical Oncology 22: 1542-45.
9. Coombes, R. Charles; Hall, Emma; Gibson, Lorna J.; et al. 2004. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. NEJM 350: 1081-1092.
10. Freedman, Benjamin. 1987. Equipoise and the Ethics of Clinical Research. NEJM 317: 141-45.
11. _; Glass, Kathleen; and Weijer, Charles. 1996. Placebo Orthodoxy in Clinical Research, II: Ethical, Legal and Regulatory Myths. Journal of Law, Medicine and Ethics 24: 253.
12. Fried, Charles. 1974. Medical Experimentation: Personal Integrity and Social Policy. Amsterdam: North-Holland Publishing Company.
13. Gifford, Fred. 1986. The Conflict between Randomized Clinical Trials and the Therapeutic Obligation. Journal of Medicine and Philosophy 11: 347-66.
14. _. 1995. Community-Equipoise and the Ethics of Randomized Clinical Trials. Bioethics 9 (2): 127-48.
15. Gigerenzer, Gerd; Swijtink, Zeno; Porter, Theodore; et al. 1989. The Empire of Chance: How Probability Changed Science and Everyday Life. Cambridge, England: Cambridge University Press.
16. Goss, Paul E.; Ingle, James; Martino, Silvana; et al. 2003. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. NEJM 349: 1793-1802.
17. Hellman, Samuel, and Hellman, Deborah. 2004. To the editor. NEJM 350: 728.
18. Hill, A. Bradford. 1951. The Clinical Trial. British Medical Bulletin 7: 278-82.
19. _. 1952. The Clinical Trial. NEJM 247: 113-19.
20. Horton, Richard. 2004. Vioxx, the Implosion of Merck, and Aftershocks at the FDA. Lancet 364: 1995-96.
21. Jennison, Christopher, and Turnbull, Bruce W. 2000. Group Sequential Methods with Applications to Clinical Trials. Boca Raton: Chapman and Hall.
22. Marquis, Don. 1983. Leaving Therapy to Chance. Hastings Center Report 13 (4): 40-47.
23. McPherson, Klim. 1974. Statistics: The Problem of Examining Accumulating Data More than Once. NEJM. 290: 501-2.
24. Meier, Paul. 1975. Statistics and Medical Experimentation. Biometrics 31: 511-29.
25. _. 1979. Terminating a Trial - The Ethical Problem. Clinical Pharmacology and Therapeutics 25: 633-40.
26. Miller, Franklin G., and Brody, Howard. 2003. A Critique of Clinical Equipoise: Therapeutic Misconception in the Ethics of Clinical Trials. Hastings Center Report 33 (3):19-28.
27. _, and Rosenstein, Donald L. 2003. The Therapeutic Orientation to Clinical Trials. NEJM 348: 1383-86.
28. National Cancer Institute. 2003. Common Terminology Criteria for Adverse Events v3.0. Published 12 December. Available at http://ctep.cancer.gov/ reporting/ctc.html.
29. O'Brien, Peter C., and Fleming, Thomas R. 1979. A Multiple Testing Procedure for Clinical Trials. Biometrics 35: 549-56.
30. Omenn, Gilbert S.; Goodman, Gary E.; Thornquist, Mark D.; et al. 1996. Risk Factors for Lung Cancer and for Intervention Effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. Journal of the National Cancer Institute 88: 1550-59.
31. Piccart-Gebhart, Martine. 2004. New Stars in the Sky of Treatment for Early Breast Cancer. NEJM 350: 1140-42.
32. Sydes, Matthew R.; Spiegelhalter, David J.; Altman, Douglas G.; et al. 2004. Systematic Qualitative Review of the Literature on Data Monitoring Committees for Randomized Controlled Trials. Clinical Trials 1: 60-79.
33. Weijer, Charles, and Miller, Paul B. 2003. Therapeutic Obligation in Clinical Research. Hastings Center Report 33 (3): 3.
34. Wertheimer, Alan. 1996. Exploitation. Princeton, NJ: Princeton University Press.
35. Writing Group for the Women's Health Initiative Investigators. 2002. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women's Health Initiative Randomized Controlled Trial. JAMA 288: 321-33.